Company: DERM
Filing Date: 2025-02-05
Form Type: 8-K
Source: 0001104659-25-009641
Chunk: 1

Company: Journey Medical Corp
Filing Date: 2025-02-05
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01      Other Events.  

On February 5, 2025, Journey Medical will
be hosting a conference call to provide an update on the commercial launch plan for the Company’s recently approved dermatological
product, Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29. A copy of the slide
presentation that Journey Medical will present during this call is attached to this Current Report on Form 8-K as Exhibit 99.1.